Soleil Boughton Sells 54,153 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 54,153 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $29.90, for a total transaction of $1,619,174.70. Following the sale, the insider now owns 165,650 shares of the company’s stock, valued at approximately $4,952,935. The trade was a 24.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Monday, January 6th, Soleil Boughton sold 268,932 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.75, for a total transaction of $7,462,863.00.
• On Tuesday, November 26th, Soleil Boughton sold 2,343 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.90, for a total transaction of $70,055.70.
• On Tuesday, October 29th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The stock was sold at an average price of $23.16, for a total transaction of $54,171.24.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS traded up $1.18 during midday trading on Thursday, reaching $30.90. 9,482,037 shares of the company’s stock were exchanged, compared to its average volume of 10,299,667. The firm’s 50 day simple moving average is $27.78 and its two-hundred day simple moving average is $22.03. The stock has a market cap of $6.75 billion, a price-to-earnings ratio of 70.22 and a beta of 1.31. Hims & Hers Health, Inc. has a fifty-two week low of $8.51 and a fifty-two week high of $35.02.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Hims & Hers Health’s revenue for the quarter was up 77.1% on a year-over-year basis. During the same period last year, the business posted ($0.04) EPS. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HIMS has been the topic of several recent analyst reports. Canaccord Genuity Group increased their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, December 2nd. Citigroup downgraded shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and raised their price target for the company from $24.00 to $25.00 in a report on Friday, January 10th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. BTIG Research began coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target on the stock. Finally, Needham & Company LLC lifted their price target on shares of Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a report on Monday, January 6th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $25.13.

Institutional Trading of Hims & Hers Health

Several institutional investors and hedge funds have recently modified their holdings of the business. Quest Partners LLC increased its position in Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after purchasing an additional 807 shares during the last quarter. Stonekeep Investments LLC raised its holdings in shares of Hims & Hers Health by 5.5% during the fourth quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock worth $410,000 after purchasing an additional 882 shares during the period. CWM LLC increased its holdings in shares of Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after acquiring an additional 1,054 shares during the period. Cadent Capital Advisors LLC increased its holdings in shares of Hims & Hers Health by 1.5% in the 4th quarter. Cadent Capital Advisors LLC now owns 72,160 shares of the company’s stock worth $1,745,000 after acquiring an additional 1,060 shares during the period. Finally, Raleigh Capital Management Inc. increased its holdings in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 1,100 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.